Shun Kishimoto1, Nobu Oshima2, Matthew Rinker3, Murali C Krishna1, Naoko Takebe4. 1. Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 3. Theradex Oncology, Princeton, NJ 08540, USA. 4. Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville, MD 20892, USA. Electronic address: takeben@mail.nih.gov.
Abstract
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant and debilitating side effect. However, there have been no studies of the relative risk of CIPN with known causative agents. We examined the risk of CIPN in patients taking such agents as a part of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program-sponsored phase I trials. METHODS: CIPN events in each patient were graded according to the Clinical Terminology of Common Adverse Effects and compared among several high-risk chemotherapeutic agent groups, adjusting for possible confounding factors. Patients receiving tubulin-targeted agents were analysed separately for specific background factors associated with CIPN. RESULTS: In 135 phase I clinical trials, 259 of 3614 patients were identified as developing CIPN during chemotherapy. Tubulin-targeting agents and proteasome inhibitors were identified as high-risk agents (hazard ratio 9.04 and 5.01, respectively) for CIPN, whereas platinum-complex agents and thalidomide analogues imparted lower risk (hazard ratio 1.52 and 1.11, respectively). Age, sex and medical history of diabetes were not significantly related to CIPN. CIPN developed over time as the number of chemotherapy cycles increased. Among patients with CIPN, treatment with tubulin-targeting agents resulted in a significantly higher rate of chemotherapy schedule modification compared with treatments with other chemotherapeutic agents. CONCLUSIONS: Tubulin-targeting agents and proteasome inhibitors were associated with a greatly increased risk of CIPN compared with other agents. CIPN tended to develop in later chemotherapy cycles. These findings will help to minimise the risk of CIPN by encouraging increased surveillance and earlier dose adjustment of high-risk agents in phase I trials. Published by Elsevier Ltd.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant and debilitating side effect. However, there have been no studies of the relative risk of CIPN with known causative agents. We examined the risk of CIPN in patients taking such agents as a part of the National Cancer Institute (NCI) Cancer Therapy Evaluation Program-sponsored phase I trials. METHODS: CIPN events in each patient were graded according to the Clinical Terminology of Common Adverse Effects and compared among several high-risk chemotherapeutic agent groups, adjusting for possible confounding factors. Patients receiving tubulin-targeted agents were analysed separately for specific background factors associated with CIPN. RESULTS: In 135 phase I clinical trials, 259 of 3614 patients were identified as developing CIPN during chemotherapy. Tubulin-targeting agents and proteasome inhibitors were identified as high-risk agents (hazard ratio 9.04 and 5.01, respectively) for CIPN, whereas platinum-complex agents and thalidomide analogues imparted lower risk (hazard ratio 1.52 and 1.11, respectively). Age, sex and medical history of diabetes were not significantly related to CIPN. CIPN developed over time as the number of chemotherapy cycles increased. Among patients with CIPN, treatment with tubulin-targeting agents resulted in a significantly higher rate of chemotherapy schedule modification compared with treatments with other chemotherapeutic agents. CONCLUSIONS: Tubulin-targeting agents and proteasome inhibitors were associated with a greatly increased risk of CIPN compared with other agents. CIPN tended to develop in later chemotherapy cycles. These findings will help to minimise the risk of CIPN by encouraging increased surveillance and earlier dose adjustment of high-risk agents in phase I trials. Published by Elsevier Ltd.
Authors: Alexander Drilon; Anne A Eaton; Katja Schindler; Mrinal M Gounder; David R Spriggs; Pamela Harris; S Percy Ivy; Alexia Iasonos; Mario E Lacouture; David M Hyman Journal: Cancer Date: 2016-02-24 Impact factor: 6.860
Authors: Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon Journal: Pain Date: 2014-09-23 Impact factor: 6.961
Authors: Sophie Postel-Vinay; Carlos Gomez-Roca; L Rhoda Molife; Bhavesh Anghan; Antonin Levy; Ian Judson; Johann De Bono; Jean-Charles Soria; Stan Kaye; Xavier Paoletti Journal: J Clin Oncol Date: 2011-03-28 Impact factor: 44.544
Authors: H Gogas; F Shapiro; C Aghajanian; D Fennelly; L Almadrones; W J Hoskins; D R Spriggs Journal: Gynecol Oncol Date: 1996-04 Impact factor: 5.482
Authors: Susanna B Park; Cindy S Y Lin; Arun V Krishnan; David Goldstein; Michael L Friedlander; Matthew C Kiernan Journal: Oncologist Date: 2011-04-08